COVID-19 continues to cause a more significant burden than #influenza in the U.S. For both infectious diseases, activity, hospitalizations, and deaths tend to follow peaks during the traditional winter viral respiratory season, however, influenza typically drops below endemic levels at certain points, while #COVID19 is responsible for significant burden throughout the year. Learn more: https://lnkd.in/gvZjuJEf
Moderna
Biotechnology Research
Cambridge, Massachusetts 601,468 followers
Our mission is to deliver the greatest possible impact to people through mRNA medicines.
About us
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. To learn more, visit www.modernatx.com. This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).
- Website
-
https://www.modernatx.com/?tc=soc_7y8qkt&cc=1004
External link for Moderna
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2010
- Specialties
- Biotechnology and mRNA Therapeutics
Locations
-
Primary
200 Technology Sq
Cambridge, Massachusetts 02139, US
-
1 Upland Rd
Norwood, Massachusetts 02062, US
Employees at Moderna
-
Jean-Christophe Wüthrich
Business Technology Management | Strategic Planning & IT Governance | Service Management, Integration & Performance | Change Management | Sourcing…
-
Shawn Lipstein
Innovative UX Leader | Critical Design Thinker | Strategic Visionary | Empathetic Manager | Driven Partner | Crystal Clear Communicator
-
Lukasz Wielochowski
Head of Moderna Enterprise Solution Hub in Poland
-
Karen Doolittle
Associate Director, Pharmacovigilance Operations - Project Management (PgMP/PMP)
Updates
-
Long COVID is a complex chronic condition caused by a COVID-19 infection, that can manifest as potentially hundreds of symptoms in many different body systems. Some health effects of #LongCOVID, such as chronic fatigue and cognitive impairment (sometimes referred to as brain fog), can affect a person’s ability to work or attend school for an extended period of time. Learn more about Long COVID in a new report from The National Academies of Sciences, Engineering, and Medicine: https://lnkd.in/egPMXpzE
-
Moderna and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna’s mRNA respiratory vaccine portfolio in Japan, including Moderna’s COVID-19 vaccine. Learn more: https://lnkd.in/eNE5P_Tj.
-
Happy #FourthofJuly from all of us at Moderna! We hope you enjoy a fun, safe, and healthy celebration with your loved ones. #IndependenceDay
-
Last week, we celebrated the official opening of our global headquarters in Cambridge, MA - a purpose-built space intended to fuel our next chapter of discovery. Thank you to all of the dignitaries, partners, community members, and employees who joined us in celebrating this momentous occasion. Read more: https://lnkd.in/eGxRRyyu
-
We announced today a project award through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic #influenza #vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Learn more: https://lnkd.in/e53E2QVH
-
What is a #booster dose of a #vaccine? How does it help? And how is that different from an updated vaccine? 💉🧬 Watch the latest episode of #CoffeeBreakScience, featuring Clinton Ogega, Ph.D., to find out! ☕🔎
-
In recognition of #CMVAwarenessMonth, we were joined by two incredible speakers who shed light on the importance of understanding and combating #cytomegalovirus (CMV). Dr. Suresh Boppana, who has been studying maternal and congenital cytomegalovirus (cCMV) infection for over 25 years, discussed the overall burden of cCMV, the significance of HCP-led conversations with women, and a breakdown of ongoing research around cCMV. Michelle, mother of a child who was born with congenital CMV, spoke about her family's journey navigating a medical landscape that is often misinformed and lacks resources to discuss the risks of CMV during pregnancy. We are grateful for Michelle and Dr. Boppana for taking the time to speak with our team! #StopCMV #NowIKnowCMV
-
We announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRNA-1345, an mRNA respiratory syncytial virus (RSV) vaccine. RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. It causes a particularly high burden of disease in infants and older adults. In the European Union, RSV is estimated to cause approximately 160,000 hospital admissions in adults each year, with 92% of these admissions occurring in adults aged 65 and over. Learn more: https://lnkd.in/ey5GauYm
-
🌟 Continuing the Celebration! 🌟 In celebration of our new global headquarters, we invited all employees to assemble STEM kits for STEAM Ahead, a nonprofit uplifting underrepresented communities by transformative STEAM programs. We also partnered with Life Science Cares Boston to host students from Alexander Twilight Academy for a building tour, experiments with a few of our scientists, and a window into STEM careers at Moderna. #ModernaGivesBack